CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis

Article metrics

Abstract

Studies on the effect of cytochrome P450 2C9 (CYP2C9), vitamin K epoxide reductase complex subunit 1 (VKORC1), and cytochrome P450 4F2 (CYP4F2) polymorphisms on warfarin maintenance dose in children are conflicting. We conducted a systematic review and meta-analysis to evaluate the effect of these polymorphisms on warfarin maintenance dose in children. We searched relevant literature using the MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trial libraries without any language restrictions from their inception to 23 July 2017. Dose differences are expressed as standardized mean difference (SMD) or mean difference (MD) with 95% confidence intervals (CI). This review was registered in the PROSPERO prospective register of systematic reviews (CRD42015016172). We included a total of nine studies (745 participants) in the meta-analysis. Patients with CYP2C9 *1/*2, *1/*3, *2/*2, *2/*3, or *3/*3 required a lower warfarin maintenance dose compared with patients with CYP2C9 *1/*1 (SMD = −0.610, 95% CI: −0.802 to −0.419, I2 = 0%). Patients with VKORC1-1639GA or AA required a lower warfarin maintenance dose compared with patients with VKORC1-1639GG (SMD = −0.666, 95% CI: −0.887 to −0.445, I2 = 33%). However, no associations were observed between CYP4F2 polymorphisms and warfarin maintenance dose (MD = 0.005 mg/kg/day, 95% CI: −0.006 to 0.015, I2 = 0%). These results were not affected by a sensitivity analysis. Our meta-analysis provides evidence that CYP2C9 and VKORC1 variant statuses affect warfarin maintenance dose in children, but not CYP4F2.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. 1.

    Oake N, Jennings A, Forster AJ, Fergusson D, Doucette S, van Walraven C. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ. 2008;179:235–44.

  2. 2.

    Jonas DE, McLeod HL. Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci. 2009;30:375–86.

  3. 3.

    Kamali F, Wynne H. Pharmacogenetics of warfarin. Annu Rev Med. 2010;61:63–75.

  4. 4.

    Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. New Engl J Med. 2011;364:1144–53.

  5. 5.

    Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. New Engl J Med. 2005;352:2285–93.

  6. 6.

    Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. New Engl J Med. 2009;360:753–64.

  7. 7.

    Li C, Schwarz UI, Ritchie MD, Roden DM, Stein CM, Kurnik D. Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood. 2009;113:3925–30.

  8. 8.

    Yang L, Ge W, Yu F, Zhu H. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement-a systematic review and meta analysis. Thrombosis Res. 2010;125:e159–66.

  9. 9.

    Liang R, Wang C, Zhao H, Huang J, Hu D, Sun Y. Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis. Thrombosis Res. 2012;130:38–44.

  10. 10.

    Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017;102:397–404.

  11. 11.

    Biss TT, Avery PJ, Brandao LR, Chalmers EA, Williams MD, Grainger JD, et al. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood. 2012;119:868–73.

  12. 12.

    Hirai K, Hayashi H, Ono Y, Izumiya K, Tanaka M, Suzuki T, et al. Influence of CYP4F2 polymorphisms and plasma vitamin K levels on warfarin sensitivity in Japanese pediatric patients. Drug Metab Pharmacokinet. 2013;28:132–7.

  13. 13.

    Kamal El-Din MA, Farhan MS, El Shiha RI, El-Kaffas RM, Mousa SM. Frequency of CYP2C9 and VKORC1 gene polymorphisms and their influence on warfarin dose in Egyptian pediatric patients. Paediatr Drugs. 2014;16:337–41.

  14. 14.

    Kato Y, Ichida F, Saito K, Watanabe K, Hirono K, Miyawaki T, et al. Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients. Drug Metab Pharmacokinet. 2011;26:295–9.

  15. 15.

    Moreau C, Bajolle F, Siguret V, Lasne D, Golmard JL, Elie C, et al. Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood. 2012;119:861–7.

  16. 16.

    Nguyen N, Anley P, Yu MY, Zhang G, Thompson AA, Jennings LJ. Genetic and clinical determinants influencing warfarin dosing in children with heart disease. Pediatr Cardiol. 2013;34:984–90.

  17. 17.

    Nowak-Gottl U, Dietrich K, Schaffranek D, Eldin NS, Yasui Y, Geisen C, et al. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood. 2010;116:6101–5.

  18. 18.

    Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, et al. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Pediatr Blood cancer. 2014;61:1055–62.

  19. 19.

    Vear SI, Ayers GD, Van Driest SL, Sidonio RF, Stein CM, Ho RH. The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population. Br J Haematol. 2014;165:832–5.

  20. 20.

    Zhang J, Tian L, Zhang Y, Shen J. The influence of VKORC1 gene polymorphism on warfarin maintenance dosage in pediatric patients: a systematic review and meta-analysis. Thrombosis Res. 2015;136:955–61.

  21. 21.

    Zhang J, Tian L, Huang J, Huang S, Chai T, Shen J. Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: a systematic review and meta-analysis. Cardiovasc Ther. 2017;35:26–32.

  22. 22.

    Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. 2008. http://handbook.cochrane.org/index.htm#part_3_special_topics.html. Accessed 14 Jan 2018.

  23. 23.

    Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.

  24. 24.

    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006–12.

  25. 25.

    Takeuchi M, Kobayashi T, Brandao LR, Ito S. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis. Syst Rev. 2016;5:105.

  26. 26.

    Wells G, Shea B, O’Connell DL, Peterson J, Welch V, Losos M, et al. The Newcastle–Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis. Appl Engi Agri. 2014;18:727–34.

  27. 27.

    Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, et al. Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE statement. Eur J Epidemiol. 2009;24:37–55.

  28. 28.

    Flockhart DA, O’Kane D, Williams MS, Watson MS, Flockhart DA, Gage B, et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008;10:139–50.

  29. 29.

    DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin trials. 1986;7:177–88.

  30. 30.

    Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.

  31. 31.

    Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence-publication bias. J Clin Epidemiol. 2011;64:1277–82.

  32. 32.

    Biss T, Hamberg AK, Avery P, Wadelius M, Kamali F. Warfarin dose prediction in children using pharmacogenetics information. Br J Haematol. 2012;159:106–9.

  33. 33.

    Hamberg AK, Friberg LE, Hanseus K, Ekman-Joelsson BM, Sunnegardh J, Jonzon A, et al. Warfarin dose prediction in children using pharmacometric bridging-comparison with published pharmacogenetic dosing algorithms. Eur J Clin Pharmacol. 2013;69:1275–83.

  34. 34.

    Lojo L, Duconge J, Santiago-Borrero P. Integrating combinatorial CYP2C9 and VKORC1 genotypes into clinical warfarin management in Puerto Rican children with thrombosis: an illustrative case study. Abstract presented at 23rd Annual Meeting of the American Society of Pediatric Hematology/Oncology (ASPHO), Montreal, Quebec; 2010.

  35. 35.

    Mitchell LG, Nowak-Gottl U, Schaffranek D, et al. The CYP4F2 V433M Polymorphism does not correlate with vitamin k antagonist dosing in a pediatric population. In: 23rd Congress of the International Society on Thrombosis and Haemostasis 57th Annual SSC Meeting. Kyoto, Japan; 2011. p. 437.

  36. 36.

    Bomgaars L, Massicotte MP, Thornburg C, et al. Pharmacogenetic expert dosing strategies (PEDS) for warfarin. J Thrombosis Haemost. 2011;9:287–287.

  37. 37.

    Hamberg AK, Wadelius M, Friberg LE, Biss TT, Kamali F, Jonsson EN. Characterizing variability in warfarin dose requirements in children using modelling and simulation. Br J Clin Pharmacol. 2014;78:158–69.

  38. 38.

    Beaune P. Pharmacogenetics and other factors in individualization of oral anti-vitamine k anti-coagulants. Clin Ther. 2013;35:e113.

  39. 39.

    Lala M, Burckart GJ, Takao CM, Pravica V, Momper JD, Gobburu JV. Genetics-based pediatric warfarin dosage regimen derived using pharmacometric bridging. J Pediatr Pharmacol therapeutics. 2013;18:209–19.

  40. 40.

    Hawcutt DB, Ghani AA, Sutton L, Jorgensen A, Zhang E, Murray M, et al. Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects. Pharmacogenomics J. 2014;14:542–8.

  41. 41.

    Tabib A, Najibi B, Dalili M, Baghaei R, Poopak B. Enzyme polymorphism in warfarin dose management after pediatric cardiac surgery. Res Cardiovasc Med. 2015;4:e27963.

  42. 42.

    Dilge Taskin B, Kula S, Ergun MA, Altun D, Olgunturk R, Tunaoglu FS, et al. The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population. Anatol J Cardiol. 2016;16:791–6.

  43. 43.

    Marek E, Momper JD, Hines RN, Takao CM, Gill JC, Pravica V, et al. Prediction of warfarin dose in pediatric patients: an evaluation of the predictive performance of several models. J Pediatr Pharmacol Ther. 2016;21:224–32.

  44. 44.

    Wakamiya T, Hokosaki T, Tsujimoto S, Kadota K, Nakano Y, Watanabe S, et al. Effect of VKORC1, CYP2C9, CFP4F2, and GGCX gene polymorphisms on warfarin dose in Japanese pediatric patients. Mol diagnosis Ther. 2016;20:393–400.

  45. 45.

    Monagle P, Chan AKC, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-Gottl U, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e737S–e801S.

  46. 46.

    Danese E, Montagnana M, Johnson JA, Rettie AE, Zambon CF, Lubitz SA, et al. Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. Clin Pharmacol Ther. 2012;92:746–56.

  47. 47.

    Cioffi M, Molinari AM, Gazzerro P, Di Finizio B, Fratta M, Deufemia A, et al. Serum osteocalcin in 1634 healthy children. Clin Chem. 1997;43:543–5.

  48. 48.

    Theuwissen E, Magdeleyns EJ, Braam LA, Teunissen KJ, Knapen MH, Binnekamp IA, et al. Vitamin K status in healthy volunteers. Food Funct. 2014;5:229–34.

Download references

Acknowledgements

We acknowledge Alanna Marson, a reference and instruction librarian of the hospital library and archives at the hospital for sick children, for help with the literature search. We also thank Conn Hastings, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this paper.

Author information

SI and LRB initiated the study planning and all contributed to the study design. MT collected data, performed statistical analysis, interpreted the results, and drafted the paper. TK designed the study and collected data. TB, FK, SV, RH, KS, BC, AH, MW, HK, MT, TW, MY, KH, and KI provided data for the study. TK, LRB, and SI critically revised the paper. All authors read, provided feedback, and approved the final paper.

Correspondence to Shinya Ito.

Ethics declarations

Conflict of interest

SI received grants from Novartis Pharma AG, grants from UCB Pharma Gmbh, personal fees from AbbVie, outside the submitted work; and he is a member of the American Society of Clinical Pharmacology & Therapeutics, and the Canadian Society of Pharmacology and Therapeutics. He is also one of the Associate Editors of “Clinical Pharmacology & Therapeutics”, which conducts peer-review and publishes articles, some of which include CPIC guidelines and original articles on pharmacogenomics/genetics. The remaining authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Takeuchi, M., Kobayashi, T., Biss, T. et al. CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis. Pharmacogenomics J (2019) doi:10.1038/s41397-019-0117-x

Download citation